Candel Therapeutics Q1 EPS $(0.28) Up From $(0.30) YoY
Portfolio Pulse from Benzinga Newsdesk
Candel Therapeutics (NASDAQ:CADL) reported a Q1 EPS loss of $(0.28), marking a 6.67% improvement from the $(0.30) per share loss reported in the same quarter last year.
May 14, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Candel Therapeutics reported a smaller loss per share in Q1 compared to last year, indicating a positive trend in its financial performance.
The improvement in EPS, even though still a loss, suggests a positive direction in Candel Therapeutics' financial health. This could lead to increased investor confidence and potentially a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100